Welcome Terry! Terry is joining this semester on exchange from University of Adelaide (Hugh Harris's Group).
20 Feb 2024METAL in PharMacEuTicAL
The simple inorganic platinum compound cis-diamminedichloroplatinum(II), also known as cisplatin, is one of the most important anticancer drug in clinical use. The discovery of its antitumoural activity by Barnett Rosenberg some 40 years ago opened a new area of anticancer research based on metal complexes.
In the Laboratory of Bioinorganic Chemistry, headed by Dr. Ang Wee Han, we are interested in taking the development of these metal complexes to a whole new level. Our research involves the study of the "metal" in pharmaceutical drugs for cancer therapy. Using rational drug design, we explore alternative strategies and analytical tools to develop viable chemotherapeutic agents based not only on platinum but also other metal centres.
Laboratory Group Members at S9 Lawn; (Photo taken Nov 2022)
Back row L-R: Boon Shing, Max, Chao Shun, Zhi Chiaw, Wee Han;
Front row L-R: Meng Rui, Kimberly, Jiao Xia, Stephen, Weng Cheng, Jia Xuan
Featured Publications
- , Using Machine Learning to Predict the Antibacterial Activity of Ruthenium Complexes, Angew. Chem. Int. Ed., 2024, in press
- , Harnessing Transition Metal Scaffolds for Targeted Antibacterial Therapy, Angew. Chem. Int. Ed., 2023, 62, e202310040
- , Targeting Pathogenic Formate-Dependent Bacteria with a Bioinspired Metallo–Nitroreductase Complex, J. Am. Chem. Soc., 2023, 145, 6453-6461
- , Targeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II, Coord. Chem. Rev., 2023, 475, 214899
- , Targeting emerging cancer hallmarks by transition metal complexes: Cancer stem cells and tumor microbiome. Part I, Coord. Chem. Rev., 2023, 475, 214923
- , Targeted Antibacterial Strategy Based on Reactive Oxygen Species Generated from Dioxygen Reduction Using an Organoruthenium Complex, JACS Au, 2021, 1, 1348-1354
- , Interfering with Metabolic Profile of Triple-Negative Breast Cancer using Rationally-Designed Metformin Prodrugs, Angew. Chem. Int. Ed., 2021, 60, 13405-13413
- , A Cisplatin‐Selective Fluorescent Probe for Real‐Time Monitoring of Mitochondrial Platinum Accumulation in Living Cells, Angew. Chem. Int. Ed., 2021, 60, 9264-9269
- , “Illuminating” Echinocandins’ Mechanism of Action, ACS Cent. Sci., 2020, 6, 1651-1653
- , PlatinER: A Highly Potent Anticancer Platinum(II) Complex that Induces Endoplasmic Reticulum Stress Driven Immunogenic Cell Death, Angew. Chem. Int. Ed., 2020, 59, 19070-19078
- , Harnessing Endogenous Formate for Antibacterial Prodrug Activation by in cellulo Ruthenium-Mediated Transfer Hydrogenation Reaction, Angew. Chem. Int. Ed., 2020, 59, 9314-9318
- , A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1, Proc. Natl. Acad. Sci. U. S. A., 2019, 116, 13943-13951
- , Dual-Targeting Dual-Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity (VIP), Angew. Chem. Int. Ed., 2019, 58, 8109-8114
- , A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes, Angew. Chem. Int. Ed., 2019, 58, 164-167
- , Apoptosis-independent organoruthenium anticancer complexes that overcome multidrug resistance: self-assembly and phenotypic screening strategies , Chem. Sci., 2017, 8, 3641-3649
- , Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance, Chem. Sci., 2016, 7, 4117-4124
- , Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes (VIP), Angew. Chem. Int. Ed. , 2015, 54, 6483-6487
- , Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents, Angew. Chem. Int. Ed., 2014, 26, 6752-6756
- , A Fluorescent Probe for Investigating the Activation of Anticancer Platinum(IV) Prodrugs Based on the Cisplatin Scaffold, Angew. Chem. Int. Ed., 2013, 52, 11785-11789
